IMPROVEMENT OF EFFICACY AND SAFETY PROFILE OF SIMVASTATIN IN COMPARISON TO REFERENCE PRODUCT (ZOCOR TABLETS) USING NANOPARTICULATE FORMULATION APPROACH
Keywords:
Nanoparticles, Simvastatin, Dose reduction, HFD model, Myopathy, HMG CoAAbstract
Objective: Simvastatin, a HMG-CoA reductase inhibitor widely used in the treatment of Hyper (dys) lipidemia causes myotoxicity and hepatotoxicity. These safety issues limit dose of Simvastatin, lead to additional monitoring of the patients as well as discontinuation of therapy. To alleviate the adverse effects and to improve efficacy and safety profile, Simvastatin was encapsulated in the nanoparticulate formulation and compared with marketed reference formulation (Zocor tablets). Methods: The nano particles (NPs) were prepared using single emulsion diffusion method and optimized for particle size, PDI, zeta potential, encapsulation efficiency. Results: The efficacy and safety of final formulation were evaluated in HFD induced hyperlipidemic albino rats. The results suggested that the NPs have significant improvement of efficacy and reduction of the toxicity in comparison to marketed reference formulation. Conclusion: By encapsulating the Simvastatin in the NPs, the 50% dose reduction can be achieved without compromising efficacy.Downloads
References
Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low-density lipoprotein subclasses. Atherosclerosis 2000;148;387-96.
Wilbert S. Management of hyperlipidemia with statins in the older patient. Clin Interventions Aging 2006;1:433–8.
https://www.medicines.org.uk/emc/medicine/29845. [Last accessed on 02 Jan 2016].
McNaughton H, Mumford CJ, Warlow CP. Simvastatin-induced rhabdomyolysis. Eur J Neurol 1994;1:175-6.
Al-Jubouri MA, Briston PG, Sinclair D, Chinn RH, Young RM. Myxoedema revealed by simvastatin-induced myopathy. Br Med J 1994;308:588.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm200635.htm [Last accessed on 02 Jan 2016].
Abdelwahed W, Degobert G, Stainless S, Fessi H. Freeze-drying of nanoparticles: formulation, process, and storage considerations. Adv Drug Deliver Rev 2006;58:1688–713.
Modi S, Anderson BD. Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method. Mol Pharm 2013;10:3076-89.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf. [Last accessed on 02 Jan 2016].
Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MNV. The design of biodegradable nanoparticles for oral delivery of doxorubicin: In vivo pharmacokinetics and toxicity studies in rats. Pharm Res 2008;26:492-501.
Bhandari U, Kumar V, Khanna N, Panda BP. The effect of high-fat-diet-induced obesity on cardiovascular toxicity in Wistar albino rats. Hum Exp Toxicol 2011;30:1313-21.